TWi successfully launches generic Bupropion HCl ER Tablets in TWi label

October 11, 2018. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced the official launch of Bupropion HCl ER Tablets 150mg and 300mg in TWi label.

Bupropion HCl ER Tablets are indicated for depressive disorder. According to IMS Health data, the total sales of Bupropion Hydrochloride Extended Release Tablet in the US were approximately US$760 million for the 12 months ended August 2017.

Via a well-established sales platform by its fully owned subsidiary, TWi Pharmaceuticals USA, Inc., TWi has successfully launched 5 self-owned ANDAs, including 1 first-to-file product in the US, and is continuously expanding the portfolio with more self-owned ANDA approvals as well as external partnership.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Investor Relations
Email: angela.luan@twipharma.com